Metastatic squamous cell carcinoma

Researchers are testing whether giving the immunotherapy drug cemiplimab before and after surgery can help patients with high-risk cutaneous squamous cell carcinoma, a type of skin cancer. The trial enrolls people whose cancer has features that raise the risk of it coming back, s…

This study tests whether combining three different antibodies—BI 770371, pembrolizumab, and cetuximab—can shrink tumors in people with head and neck cancer that has spread or come back. About 91 adults are randomly assigned to one of three treatment groups. The goal is to see if …

This phase II trial tests whether a combination of amivantamab and hyaluronidase works as well as cetuximab for treating skin squamous cell carcinoma that has come back or spread. The study enrolls 86 immunocompromised participants, including organ transplant recipients. The goal…

This study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…

This early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…

This study tests a combination of two drugs—cetuximab and interleukin-12—in people with advanced head and neck cancer that cannot be removed by surgery or has spread. The goal is to find the best dose and see if the combination can shrink tumors. Twenty-three participants are enr…

This study tested a drug called pembrolizumab in 157 people with rare cancers that had spread or couldn't be removed. The drug works by helping the body's immune system attack the cancer. The main goal was to see how many patients were alive and their cancer hadn't grown after 27…

This phase 2 trial tests a weekly combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy pembrolizumab in 31 patients with metastatic head and neck cancer who cannot receive the standard drug 5-fluorouracil. The goal is to see if this regimen sh…

This study tested a combination of two drugs—nab-paclitaxel (a chemotherapy) and nivolumab (an immunotherapy)—in 46 people with advanced head and neck cancer that had stopped responding to a prior immunotherapy. The goal was to see if the combo could shrink tumors or slow the can…

This study tests a three-drug combination (sorafenib, carboplatin, and paclitaxel) in 48 people with head and neck cancer that has spread or returned. The goal is to see how well the treatment shrinks tumors and delays cancer growth. Participants must have a confirmed diagnosis a…

This study tests a combination of three drugs (olaparib, pembrolizumab, and carboplatin) as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if this mix works better than the standard treatment at shrinking tumors. About 30 a…

This study aimed to see if limiting food intake to a 10-hour window each day (with 14 hours of nightly fasting) could improve how well immunotherapy works in people with advanced head/neck or kidney cancer. Researchers planned to track changes in gut bacteria and immune markers. …